Santarus "buy"

12/27/06 - Wedbush Morgan Securities

NEW YORK, December 27 (newratings.com) - Analyst Michael Higgins of Wedbush Morgan reiterates his "buy" rating on Santarus Inc (SNTS). The 12-month target price is set to $11.

In a research note published yesterday, the analyst mentions that Zegerid total prescriptions for the week ended December 15 rose by 2% on a w/w basis, with new prescriptions rising by 1%. Zegerid’s total prescription market share climbed by 0.03% to 0.58 % of the GERD market, while the drug’s new prescription market share rose by 0.02% to 0.78%, the analyst says. Wedbush Morgan expects the Zegerid 40mg capsules to continue to penetrate the Rx heartburn market.